This is mainly due to rising obesity rates, increased awareness of health risks, and the proven efficacy of Wegovy as a weight-loss medication
To date, the trial has enrolled 94 participants, with 54 in the T2DM group and 40 in the obesity group
patent expiry for GLP-1 drugs across markets Company Molecule Brand Name Mode of administration First US Patent Expiry Canada Brazil India Novo Semaglutide Ozempic Injectable 2031 Jan 2026 Mar 2026 Mar 2026 Novo Semaglutide Wegovy Injectable 2031 Jan 2026 Mar 2026 Mar 2026 Novo Semaglutide Rybelsus Oral 2031 Jan 2026 Mar 2026 Mar 2026 Eli Lilly Tirzepatide Mounjaro Injectable 2036 2036 2036 2036 Eli Lilly Tirzepatide Zepbound Injectable 2036 2036 2036 2036 Positioning of Indian Pharma companies in GLP-1s company positioning Shaily Engineering Leading manufacturer of pen injectors for GLP-1 therapies
Contrastingly, GLP1 antagonist sales in 2023 showcase a more diversified landscape, with therapeutics such as Ozempic, Trulicity, and Mounjaro driving 71 per cent of the sales. Looking ahead, the GLP1 agonist market is poised for robust growth, anticipating a 19.2 per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029
Contact Metabolic Research center to learn more about how our team can help you take the next step
